Auris Medical Holding

US: EARS

Market Cap$3.7m

Last Close $0.4

Auris Medical is a Swiss biopharmaceutical company developing neurotology and central nervous system (CNS) therapeutics. It is developing intranasal betahistine for vertigo and mental disorder supportive care. It has also begun development on AM-301 for the protection against airborne pathogens and allergens.

More Auris Medical Holding content >

Investment summary

Auris Medical is a biopharmaceutical company developing pharmacotherapies for inner ear and CNS disorders. Its primary focus is on the development of AM-125 (intranasal betahistine) for the treatment of acute vertigo. Oral betahistine has been prescribed in Europe for decades for all types of vertigo, with an average 26% market share, but is not available in the US. Auris has initiated its Phase II clinical trial in 118 patients with surgically induced acute vertigo. Enrolment in Part A has been completed and interim data showed a dose dependent improvement in balance tests over placebo. It is also developing AM-201, an intranasal betahistine formulation, for co-administration with olanzapine to counteract adverse effects, especially weight gain. Data from a Phase Ib has shown a statistically significant reduction in weight gain at the 30mg dose.

Y/E Dec
Revenue (CHFm)
EBITDA (CHFm)
PBT (CHFm)
EPS (CHFc)
P/E (x)
P/CF (x)
2018A 0.0 (11.0) (12.0) (1532.81) N/A N/A
2019A 0.0 (7.3) (7.3) (243.24) N/A N/A
2020E 0.0 (5.1) (5.4) (91.45) N/A N/A
2021E 0.0 (13.1) (14.0) (194.66) N/A N/A
Industry outlook

Acute vertigo/dizziness is one of the most common causes of visits to A&E with roughly 2.6m visits associated with the condition each year.

Last updated on 14/03/2019
Content on Auris Medical Holding
Auris – executive interview
Healthcare | Edison TV | 5 October 2020
Interview with Thomas Meyer, CEO of Auris
Healthcare | blog | 22 July 2020
View more
Register to receive research on Auris Medical Holding as it is published
Share price graph
Balance sheet
Forecast net debt (CHFm) 2.7
Forecast gearing ratio (%) 76
Price performance
%
1m
3m
12m
Actual (22.9) (15.3) (73.2)
Relative* (23.1) (23.8) (76.2)
52-week high/low US$2.0/US$0.2
*% relative to local index
Key management
Thomas Meyer CEO
Elmar Schaerli CFO